









0				
Jutpu	t and Outcon	Output Achieve		
Revised Output indicator 1	224 patients either receiving first line integrated anti-inflammatory therapy or second-tier advanced therapy (240 patients)	93%	Data retrieved from participant's enrolment / registration record	
Output indicator 3	220 patients participating in the ketamine- associated liver injury surveillance program (240 patients)	92%	Data retrieved from participant's enrolment / registration record	
Output indicator 4	356 of DTRC residents participating in health- talk and screening program for ketamine- associated urinary tract dysfunction (360 patients)	99%	Data retrieved from participant's enrolment / registration record	
Output indicator 5	89% (8/9) of patients identified to be "high risk" cases for ketamine-associated liver injury received advanced hepatological assessment by hepatologists (80%)	89%	Data retrieved from participant's enrolment / registration record	
Output indicator 6	100% (28/28) DTRC residents identified with significant urinary tract dysfunction symptoms received formal urological treatment at YUTC (80%)	100%	Data retrieved from participant's enrolment / registration record	6

			All the		
Outpu	t and Outcome Evaluation				
	Description of Indicator	Outcome Achieved	Evaluation Methods		
Outcome indicator 1	Improvement in urinary tract dysfunction symptoms or voiding function among patients who received first-line integrated anti- inflammatory therapy (70% showed improvement in urinary tract dysfunction symptoms or voiding function <u>or</u> significant improvement as indicated by paired t- test)	80% (98/123) of the participants improved after the first-line treatment.	Clinical data <u>or</u> Pelvic Pain and Urinary Urgency/Frequency (PUF) Symptom Scale <u>or</u> uroflometry parameters (Pre-test and Post-test assessment)		
Outcome indicator 2	Improvement in urinary tract dysfunction symptoms or voiding function among patients who received second-tier advanced therapy (50% showed improvement in urinary tract dysfunction symptoms or voiding function <u>or</u> significant improvement as indicated by paired t- test)	76% (16/21) of the participants improved after the second-tier treatment.	Clinical data <u>or</u> Pelvic Pain and Urinary Urgency/Frequency (PUF) Symptom Scale <u>or</u> uroflometry parameters (Pre-test and Post-test assessment)		







